Mizuho Issues Pessimistic Forecast for Autolus Therapeutics (NASDAQ:AUTL) Stock Price

Autolus Therapeutics (NASDAQ:AUTL) had its price objective reduced by stock analysts at Mizuho from $12.00 to $10.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock.

Other research analysts have also recently issued research reports about the company. Truist Financial raised Autolus Therapeutics to a “strong-buy” rating in a research note on Wednesday, March 25th. Zacks Research raised Autolus Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Friday, March 13th. HC Wainwright started coverage on Autolus Therapeutics in a research report on Tuesday, February 17th. They issued a “buy” rating and a $9.00 price objective on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $10.00 target price on shares of Autolus Therapeutics in a research note on Friday, March 27th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Autolus Therapeutics in a research note on Wednesday, January 21st. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Autolus Therapeutics has an average rating of “Moderate Buy” and an average price target of $8.50.

Autolus Therapeutics Stock Performance

AUTL stock opened at $1.38 on Tuesday. The stock has a market cap of $367.28 million, a PE ratio of -1.28 and a beta of 1.95. Autolus Therapeutics has a 12 month low of $1.11 and a 12 month high of $2.70. The company has a 50-day moving average price of $1.48 and a 200 day moving average price of $1.52.

Autolus Therapeutics (NASDAQ:AUTL) last posted its quarterly earnings data on Friday, March 27th. The company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.07). The firm had revenue of $24.29 million during the quarter, compared to analysts’ expectations of $23.92 million. Autolus Therapeutics had a negative return on equity of 99.05% and a negative net margin of 381.40%. Sell-side analysts forecast that Autolus Therapeutics will post -0.94 EPS for the current year.

Hedge Funds Weigh In On Autolus Therapeutics

Institutional investors have recently modified their holdings of the stock. R Squared Ltd raised its stake in shares of Autolus Therapeutics by 40.1% during the third quarter. R Squared Ltd now owns 30,476 shares of the company’s stock valued at $50,000 after acquiring an additional 8,730 shares in the last quarter. Tema Etfs LLC grew its stake in Autolus Therapeutics by 9.0% in the second quarter. Tema Etfs LLC now owns 120,388 shares of the company’s stock worth $274,000 after purchasing an additional 9,960 shares in the last quarter. The Manufacturers Life Insurance Company increased its holdings in Autolus Therapeutics by 41.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 38,419 shares of the company’s stock worth $88,000 after purchasing an additional 11,289 shares during the period. Invesco Ltd. increased its holdings in Autolus Therapeutics by 53.3% during the 1st quarter. Invesco Ltd. now owns 32,738 shares of the company’s stock worth $51,000 after purchasing an additional 11,381 shares during the period. Finally, Marex Group plc bought a new stake in Autolus Therapeutics during the 2nd quarter valued at $28,000. 72.83% of the stock is owned by hedge funds and other institutional investors.

About Autolus Therapeutics

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.